MX2014007169A - Tratamiento de trastorno autoinmune al usar agonistas de rxr. - Google Patents
Tratamiento de trastorno autoinmune al usar agonistas de rxr.Info
- Publication number
- MX2014007169A MX2014007169A MX2014007169A MX2014007169A MX2014007169A MX 2014007169 A MX2014007169 A MX 2014007169A MX 2014007169 A MX2014007169 A MX 2014007169A MX 2014007169 A MX2014007169 A MX 2014007169A MX 2014007169 A MX2014007169 A MX 2014007169A
- Authority
- MX
- Mexico
- Prior art keywords
- autoimmune disorder
- rxr agonists
- disorder treatment
- compositions
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente especificación proporciona compuestos de agonistas de RXR, composiciones que comprenden dichos agonistas de RXR, y métodos que usan tales compuestos y composiciones para tratar un trastorno autoinmune, la inflamación asociada con un trastorno autoinmune y/o un rechazo de trasplante, así como el uso de tales agonistas de RXR para fabricar un medicamento y el uso de tales compuestos y composiciones para tratar un trastorno autoinmune, inflamación asociada con el trastorno autoinmune y/o un rechazo de trasplante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570182P | 2011-12-13 | 2011-12-13 | |
PCT/US2012/069566 WO2013090616A1 (en) | 2011-12-13 | 2012-12-13 | Autoimmune disorder treatment using rxr agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014007169A true MX2014007169A (es) | 2016-03-04 |
MX352727B MX352727B (es) | 2017-12-06 |
Family
ID=48613185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007169A MX352727B (es) | 2011-12-13 | 2012-12-13 | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
Country Status (7)
Country | Link |
---|---|
US (13) | US20130190395A1 (es) |
EP (1) | EP2790698A1 (es) |
CN (2) | CN104114171A (es) |
AU (2) | AU2012352149B2 (es) |
CA (1) | CA2858882C (es) |
MX (1) | MX352727B (es) |
WO (1) | WO2013090616A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2623638A1 (en) | 2005-09-30 | 2007-04-12 | Vitae Pharmaceuticals, Inc. | Treatment of cancer with specific rxr agonists |
US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
WO2016159256A1 (ja) * | 2015-03-31 | 2016-10-06 | 国立大学法人 岡山大学 | 神経変性疾患の治療又は予防用医薬組成物 |
PL3368080T3 (pl) * | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
EP3210926B1 (en) * | 2016-02-23 | 2020-01-01 | Otis Elevator Company | Elevator service panel |
CN115252789A (zh) * | 2016-03-10 | 2022-11-01 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
NZ745704A (en) * | 2016-03-10 | 2019-04-26 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
WO2019060600A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS |
CN115010577A (zh) | 2017-11-17 | 2022-09-06 | Io治疗公司 | 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法 |
WO2020112889A2 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
US20220311492A1 (en) * | 2019-05-31 | 2022-09-29 | Qualcomm Incorporated | Csi acquisition for partial reciprocity |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5466861A (en) | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
EP0671005A1 (en) | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
WO1994014777A1 (en) | 1992-12-28 | 1994-07-07 | Eisai Co., Ltd. | Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar) |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5675033A (en) | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
EP0856001B1 (en) | 1995-10-02 | 2002-08-28 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 5ht2c receptor antagonists |
US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US20030219832A1 (en) | 1996-03-11 | 2003-11-27 | Klein Elliott S. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5739338A (en) | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
CA2274756C (en) | 1996-12-11 | 2007-03-13 | Bruce M. Spiegelman | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
AU3595099A (en) | 1998-05-11 | 1999-11-29 | Novo Nordisk A/S | New compounds, their preparation and use |
AU4676999A (en) | 1998-06-12 | 1999-12-30 | Ligand Pharmaceuticals, Inc. | Treatment of anti-estrogen resistant breast cancer using rxr modulators |
US6403638B1 (en) | 1998-10-01 | 2002-06-11 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6147224A (en) | 1998-10-01 | 2000-11-14 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6048873A (en) | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
US6043381A (en) | 1999-05-07 | 2000-03-28 | Allergan Sales, Inc. | Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives |
WO2001007028A2 (en) | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
US6187750B1 (en) | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
CA2383565A1 (en) | 1999-09-14 | 2001-03-22 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
TWI281911B (en) | 2000-04-04 | 2007-06-01 | Allergan Inc | Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents |
US20030077664A1 (en) | 2001-04-18 | 2003-04-24 | Yi Zhao | Methods of screening for compounds that modulate hormone receptor activity |
US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
RU2003134180A (ru) | 2001-05-08 | 2005-02-10 | Мерк Патент ГмбХ (DE) | Комбинированная терапия, использующая антитела к egfr и антигормональные средства |
US7173134B2 (en) | 2001-09-25 | 2007-02-06 | Smithkline Beecham Corporation | Selective RXR ligands |
US6645526B2 (en) | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1485464A4 (en) | 2002-03-18 | 2006-11-29 | Gamida Cell Ltd | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS |
US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
MXPA04011972A (es) | 2002-06-04 | 2005-03-31 | Galderma Res & Dev | Nuevos ligandos inhibidores de los receptores rars, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica. |
US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
JP4275365B2 (ja) | 2002-08-06 | 2009-06-10 | 三菱電機株式会社 | 複合形ガス絶縁開閉装置 |
US7105566B2 (en) | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
CA2505286C (en) | 2002-11-18 | 2012-02-07 | Galderma Research & Development, S.N.C. | Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics |
US7019034B2 (en) | 2003-01-28 | 2006-03-28 | Allergan, Inc. | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals |
US6936636B2 (en) | 2003-06-26 | 2005-08-30 | Allergan, Inc. | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
EP1653939A2 (en) | 2003-08-07 | 2006-05-10 | Allergan, Inc. | Method for treating cachexia with retinoid ligands |
CA2539288C (en) | 2003-09-15 | 2015-05-12 | Shaker A. Mousa | Thyroid hormone analogs and methods of use |
WO2005046726A2 (en) * | 2003-11-12 | 2005-05-26 | Allergan, Inc. | Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
ES2318453T3 (es) | 2004-01-20 | 2009-05-01 | Allergan, Inc. | Composiciones para terapia localizada del ojo, que comprenden, de preferencia,triamcinolona acetonida y acido hialuronico. |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US20090227674A1 (en) | 2005-08-18 | 2009-09-10 | Richon Victoria M | Combination methods fo saha and targretin for treating cancer |
US7723326B2 (en) * | 2005-09-30 | 2010-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
CA2623638A1 (en) | 2005-09-30 | 2007-04-12 | Vitae Pharmaceuticals, Inc. | Treatment of cancer with specific rxr agonists |
CA2624345A1 (en) * | 2005-09-30 | 2007-04-12 | Janssen Pharmaceutica N.V. | 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
KR101530050B1 (ko) | 2007-03-02 | 2015-06-22 | 주식회사 노브메타파마 | 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법 |
JP2010531138A (ja) * | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性t細胞ならびに同製造および使用方法 |
WO2009102789A2 (en) | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
ES2332169B1 (es) | 2008-07-24 | 2010-10-25 | Universidad Del Pais Vasco | Empleo de microparticulas que comprenden celulas modificadas geneticamente en el tratamiento de enfermedades neurodegenerativas. |
DK2344677T3 (en) * | 2008-10-08 | 2017-07-24 | Cambridge Entpr Ltd | METHODS AND COMPOSITIONS FOR DIAGNOSTICATION AND TREATMENT OF AUTOIMMUNIC DISEASE SECONDARY TO MULTIPLE SCLEROSIS |
WO2010041449A1 (ja) | 2008-10-09 | 2010-04-15 | 国立大学法人 岡山大学 | Rxr作動性物質を有効成分とする抗アレルギー剤 |
ES2414879T4 (es) | 2009-04-20 | 2013-10-30 | Allergan, Inc. | Hidrogeles de fibroína de seda y usos de éstos |
WO2010132671A1 (en) | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
US20100298434A1 (en) | 2009-05-21 | 2010-11-25 | Claude Rouillard | Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation |
JP2010280585A (ja) * | 2009-06-02 | 2010-12-16 | Okayama Univ | Rxr作動性物質を有効成分とする鎮痛剤 |
WO2011006157A2 (en) * | 2009-07-10 | 2011-01-13 | Case Western Reserve University | Rxr agonist compounds and methods |
US9174917B2 (en) | 2010-02-19 | 2015-11-03 | Arizona Board Of Regents On Behalf Of Arizona State University | Bexarotene analogs |
WO2012125749A2 (en) | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
EP2556827A1 (en) | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Treatment of neurodegenerative diseases |
EP2766018A4 (en) | 2011-10-13 | 2015-02-25 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND ASSOCIATED METHODS |
US9074948B2 (en) | 2011-10-19 | 2015-07-07 | Connectivity Systems Incorporated | Method for indirect food temperature measurement |
AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
WO2015059632A1 (en) | 2013-10-23 | 2015-04-30 | Acadia Pharmaceuticals Inc. | Treatment of a neurodegenerative disease or disorder |
JP2016537414A (ja) | 2013-10-29 | 2016-12-01 | ベスティオン、インク. | 心臓神経堤細胞、及びその使用方法 |
WO2016144976A1 (en) | 2015-03-09 | 2016-09-15 | Kings College London | Combination therapy with rar alpha agonists for enhancing th1 response |
WO2017075610A1 (en) | 2015-10-31 | 2017-05-04 | Io Therapeutics, Inc. | Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists |
WO2017075612A1 (en) | 2015-10-31 | 2017-05-04 | Io Therapeutics, Inc. | Treatment of cancer with combinations of rxr agonists and thyroid hormones |
PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
CN115252789A (zh) | 2016-03-10 | 2022-11-01 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
NZ745704A (en) | 2016-03-10 | 2019-04-26 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
MX2020002262A (es) | 2017-08-31 | 2020-07-20 | Io Therapeutics Inc | Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer. |
WO2019060600A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS |
CN115010577A (zh) | 2017-11-17 | 2022-09-06 | Io治疗公司 | 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法 |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
-
2012
- 2012-12-13 AU AU2012352149A patent/AU2012352149B2/en active Active
- 2012-12-13 CA CA2858882A patent/CA2858882C/en active Active
- 2012-12-13 WO PCT/US2012/069566 patent/WO2013090616A1/en active Application Filing
- 2012-12-13 MX MX2014007169A patent/MX352727B/es active IP Right Grant
- 2012-12-13 CN CN201280069683.5A patent/CN104114171A/zh active Pending
- 2012-12-13 US US13/714,051 patent/US20130190395A1/en not_active Abandoned
- 2012-12-13 CN CN201910413195.5A patent/CN110151745A/zh active Pending
- 2012-12-13 EP EP12857218.7A patent/EP2790698A1/en not_active Withdrawn
-
2015
- 2015-02-19 US US14/626,339 patent/US10034845B2/en active Active
- 2015-06-05 US US14/732,328 patent/US20150342917A1/en active Pending
-
2016
- 2016-11-02 US US15/341,969 patent/US10285960B2/en active Active
-
2017
- 2017-08-04 AU AU2017210644A patent/AU2017210644B2/en active Active
- 2017-12-22 US US15/852,580 patent/US10201512B2/en active Active
-
2018
- 2018-05-24 US US15/988,965 patent/US10695307B2/en active Active
- 2018-12-20 US US16/228,217 patent/US10945976B2/en active Active
-
2020
- 2020-01-14 US US16/742,616 patent/US11547684B2/en active Active
- 2020-01-14 US US16/742,600 patent/US20200155488A1/en not_active Abandoned
- 2020-12-18 US US17/126,787 patent/US11246845B2/en active Active
- 2020-12-18 US US17/126,714 patent/US11166927B2/en active Active
-
2021
- 2021-12-22 US US17/560,035 patent/US11576881B2/en active Active
-
2022
- 2022-01-27 US US17/586,657 patent/US11793781B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352727B (es) | Tratamiento de trastorno autoinmune al usar agonistas de rxr. | |
MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
WO2012125749A3 (en) | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS | |
MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
EP4233545A3 (en) | Synergistic bacterial compositions and methods of production and use thereof | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
IN2015DN03029A (es) | ||
EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
MX339533B (es) | Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp). | |
PH12014501032A1 (en) | 2-thiopyrimidinones | |
MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
MX360774B (es) | Antagonistas de progesterona. | |
NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
GB2548277A (en) | Antibiofilm compositions | |
MX365403B (es) | Peptidos y metodos para usarlos. | |
MX337486B (es) | Fibras de degradacion controlada. | |
EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
MX358429B (es) | Nuevos derivados de isocromano e isotiocromano agonistas del adrenoreceptor alfa2a, especialmente agonistas del adrenoreceptor alfa2a para usarse como sedantes o analgesicos. | |
MX2017004580A (es) | Combinaciones de auristatina sinergica. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |